Shree Ganesh Remedies Limited (SGRL), manufacturer of specialty, fine chemicals and pharmaceutical intermediates, owing to its expertise in organic chemistry and technology competencies, is planning Rs 600 million capex over the next two years.
SGRL has taken a step forward for future expansion in increasing the manufacturing capacity as well as upgradation in chemical reaction technologies.
Current ongoing capex expansion plans include commissioning of a new GMP plant situated in the existing facility at unit one. The plant will address the increase in customers’ demand for Key Starting Materials (KSM) and advanced pharmaceuticals Intermediates catering to big pharma firms in India as well as European Region.
The company is also in the phase of the erection for the hydrogenation plant block, which will address high-pressure reactions for pharma intermediates as well as fine chemicals.
SGRL has two manufacturing units in close proximity to each other in GIDC Ankleshwar, Gujarat with a total production capacity of more than 200 KL.
The product portfolio is inclined towards international markets, having catered to major pharma players in the European Union region and domestic Indian pharmaceutical companies.